Tag Archives: progression-free survival

New Monoclonal Antibodies Increased Survival in Lung Cancer Patients

Posted on May 30, 2011 by wngai

A new study showed that non-small-cell lung cancer (NSCLC) patients who have high level of Met proteins in their tumor can have their survival increase three-fold by receiving experimental antibody MetMAb in combination with erlotinib (Tarceva). In the trial, 137 previously-treated … Continue reading →

New Personalized Medicine Increases Survival in Melanoma Patients

Posted on April 3, 2011 by wngai

Metastatic melanoma is the deadliest and most aggressive from of skin cancer. A person with metastatic melanoma typically has a short life expectancy that is measured in months. The mainstay treatments for metastatic melanoma are dacarbazine (DTIC), interleukin-2 (IL-2) and … Continue reading →

Posted in Cancer, Melanoma | Tagged BRAF V600 mutation, dacarbazine, DTIC, Genentech, IFN, IL-2, interferon, interleukin-2, Melanoma, Metastatic melanoma, Patient Access Program, progression-free survival, RG7204, Roche, Survival | Comments Off

Bevacizumab Beneficial in Newly Diagnosed Glioblastoma?

Posted on December 22, 2010 by wngai

A large study of patients with newly diagnosed glioblastoma multiforme suggests that the addition of bevacizumab (Avastin) and irinotecan (Camptosar) to standard chemoradiation can extend survival (progression and overall survival) by 6 months. Bevacizumab (Avastin) is an inhibitor of vascular … Continue reading →

Posted in Cancer, Glioblastma | Tagged Avastin, bevacizumab, camptosar, chemoradiation, glioblastoma multiforme, Irinotecan, progression-free survival, Survival, Temodar, temozolomide | Comments Off

Afatinib Extend Time to Tumor Progression in Advanced Lung Cancer

Posted on December 22, 2010 by wngai

Currently, no treatment exists for lung cancer patients with epidermal growth-factor receptor (EGFR) mutation who have failed tyrosine kinase inhibitors, getifinib (Iressa) or erlotinib (Tarceva). However, an investigational drug, afatinib (BIBW 2992), was recently found to increase progression-free survival and … Continue reading →

Posted in Cancer, Lung Cancer, Non Small Cell Lung Cancer | Tagged Afatinib, epidermal growth-factor receptor, erlotinib, getifinib, Iressa, Lung Cancer, Non small cell lung cancer, NSCLC, platinum, progression-free survival, Tarceva, time to tumor progression, tumor shrinkage | Comments Off

Europe Approved Sutent for Rare Pancreatic Cancer

Posted on December 22, 2010 by wngai

The European Commission has recently approved Sutent (sunitinib) as a medicine for treating patients with pancreatic neuroendocrine tumors (NET). The drug is now indicated to treat unresectable metastatic, well-differentiated pancreatic NET in adults with disease progression. The approval was based … Continue reading →

Posted in Cancer, Pancreatic Cancer | Tagged metastatic, Pancreatic Cancer, pancreatic neuroendocrine tumors, progression-free survival, sunitinib, Sutent | Comments Off